Migraine With Aura Clinical Trial
Official title:
The Effect of the Selective PDE5 Inhibitor, Sildenafil, on Aura and Migraine Headache Induction.
Verified date | November 2021 |
Source | Herlev Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In a double blind placebo-controlled cross-over study the effect of Sildenafil on aura and migraine headache induction is tested in patient with migraine with aura.
Status | Completed |
Enrollment | 16 |
Est. completion date | August 2021 |
Est. primary completion date | February 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Migraine with aura - Minimum of 2 attacks/year Exclusion Criteria: - Any other type of headache, except tension-type headache < 4 days per month - History of cardio- or cerebrovascular diseases - Hypertension or hypotension - Any daily intake of medication, including prophylactic migraine treatment, except oral contraceptives - Pregnancy and lactation |
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Neurology, Herlev-Gentofte Hospital | Herlev |
Lead Sponsor | Collaborator |
---|---|
Herlev Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Aura and migraine like headache | Induction of aura reported by an aura diary for 14 hours post medication | 14 hours | |
Secondary | Markers of endothelial function in blood | 2 hours | ||
Secondary | Migraine without aura | Induction of headache resembling usual migraine attacks | 14 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02253004 -
Induction of Migraine Aura With Cilostazol
|
Phase 0 | |
Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
Completed |
NCT00123201 -
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
|
Phase 2 | |
Completed |
NCT04406649 -
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
|
Phase 3 | |
Completed |
NCT03874832 -
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05565001 -
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.
|
N/A | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Recruiting |
NCT05416476 -
Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
|
Phase 3 | |
Active, not recruiting |
NCT02906085 -
Endothelin-1 as a Potential Trigger of Migraine Aura
|
N/A | |
Recruiting |
NCT00893594 -
Efficacy of Sumatriptan With Naprosyn in Migraine With Aura
|
N/A | |
Completed |
NCT01388699 -
Migraine and Endothelial Dysfunction
|
||
Completed |
NCT00534560 -
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
|
Phase 2 | |
Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
Not yet recruiting |
NCT04063540 -
Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura
|
Phase 2 | |
Completed |
NCT03472417 -
Partial Rebreathing in the Treatment of Migraine With Aura
|
N/A | |
Completed |
NCT00334178 -
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
|
Phase 3 | |
Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
Recruiting |
NCT06414044 -
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
|
||
Completed |
NCT03472378 -
Can DFN-15 Terminate Migraine With Allodynia?
|
Phase 2 |